The inhibitory effect of celecoxib and rosiglitazone on experimental endometriosis  

Oleh:

Olivares, Carla ; Ricci, Analia ; Bilotas, Mariela ; Baranao, Rosa Ines ; Meresman, Gabriela

Jenis: Article from Journal - ilmiah internasional
Dalam koleksi: Fertility and Sterility (keterangan: ada di ClinicalKey) vol. 96 no. 02 (Aug. 2011), page 428-433.
Topik: Apoptosis; cell proliferation; COX-2 inhibitor; endometriosis; PPAR? agonist

Ketersediaan

Perpustakaan FK Nomor Panggil: F02.K.2011.04 Non-tandon: 1 (dapat dipinjam: 0) Tandon: tidak ada

Lihat Detail Induk

Isi artikel

Objective To evaluate the effects of celecoxib and rosiglitazone on the implantation and growth of endometriotic-like lesions in a murine model of endometriosis. Design Prospective experimental study. Setting Animal research and laboratory facility. Animal(s) Two-month-old female BALB/c mice. Intervention(s) Surgically induced endometriosis in female BALB/C mice; 28 days of treatment with celecoxib, rosiglitazone, or their combination; counting, measuring, excising, and fixing lesions. Main Outcome Measure(s) Immunohistochemical examination for proliferating cell nuclear antigen (PCNA), CD31, and CD34 to assess cell proliferation and vascularization, with the terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) technique for apoptosis evaluation. Result(s) Celecoxib and the combined treatment (celecoxib and rosiglitazone) statistically significantly reduced the mean number of lesions established per mouse, and all treatments diminished the implant volume. In addition, cell proliferation within the implants was statistically significantly reduced, and apoptosis was statistically significantly enhanced by all treatments. Also, we found that all treatments diminished the vascularized area in the lesion. Conclusion(s) These results are promising and reveal that celecoxib and rosiglitazone, combined or separately, have a beneficial effect on overall endometriotic growth.

Opini Anda

Klik untuk menuliskan opini Anda tentang koleksi ini!

Kembali